

PARLIAMENTARY JOINT COMMITTEE ON LAW ENFORCEMENT

PARLIAMENT HOUSE CANBERRA ACT 2600 Telephone: 02 6277 3419 Facsimile: 02 6277 5866 Email: le.committee@aph.gov.au

MEDIA RELEASE

Inquiry into vaccine related fraud and security risks

On 17 March 2021, the Parliamentary Joint Committee on Law Enforcement (committee) resolved to inquire into and report on COVID-19 vaccine related fraud and security risks.

On 26 August 2021, the committee tabled an interim report, which can be found on the <u>inquiry website here</u>. In its interim report, the committee indicated that it intended to present its final report by February 2022, after the committee had further reviewed the fraud and security risks that may arise as systems for proving vaccination status are rolled out.

The committee is renewing its call for written submissions, and requests that submissions be received by **Friday**, **29 October 2021** (although submissions received after that date can still be received). Those who have previously made a written submission are welcome to provide a supplementary updated submission if they wish.

The committee is particularly interested in hearing evidence regarding fraud risks related to proof of COVID-19 vaccination status, although it welcomes all submissions addressing the inquiry terms of reference.

The inquiry's terms of reference and further information can be found on the committee's website at: https://www.aph.gov.au/Parliamentary_Business/
https://www.aph.gov.au/Parliamentary_Business/
<a href="mail

PARLIAMENTARY JOINT COMMITTEE ON LAW ENFORCEMENT

Inquiry into vaccine related fraud and security risks

Terms of Reference

Pursuant to subsection 7(1) of the *Parliamentary Joint Committee on Law Enforcement Act 2010*, the committee will inquire into and report on vaccine related fraud and security risks, with particular reference to:

- a) Telecommunications and internet fraud relating to COVID vaccinations;
- b) Criminal activity around the supply of fake vaccines, black market vaccines and/or fake vaccine certifications and the acquisition of certificates;
- c) Risks to Australia regarding fraud and integrity of COVID vaccines in South Pacific nations and support for these nations to address issues relating to fraud and integrity risks;
- d) Physical security in the production, transport and supply of COVID vaccines in Australia;
- e) Measures to prevent and protect against COVID vaccine-related fraud and security risks;
- f) Any related matters.